Xilio Therapeutics snags $100.5m Series B
Waltham, Massachusetts-based Xilio Therapeutics, a developer of immuno-oncology therapies for patients with cancer, has secured $100.5 million in Series B financing.
Waltham, Massachusetts-based Xilio Therapeutics, a developer of immuno-oncology therapies for patients with cancer, has secured $100.5 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination